Company is Addressing Diabetes-Related Nerve Disease
WALTHAM, Mass.--(BUSINESS WIRE)--Mar 26, 2012-- NeuroMetrix, Inc.
(Nasdaq: NURO), a medical device company focused on the diagnosis and treatment of neurological complications of diabetes announced that Chief Executive Officer Shai N. Gozani, M.D., Ph.D. has been interviewed on CEONEWS.Tv, a financial news network. The interview is available at: http://www.ceonews.tv/nuro/ In the interview, Dr. Gozani discussed his vision for NeuroMetrix and the company's early success with NC-stat(R) DPNCheck(TM), a fast, accurate, and quantitative test for diabetic peripheral neuropathy (DPN). DPN is a nerve disease that affects over 50% of patients with diabetes and can lead to foot ulcers and amputation. Dr. Gozani reviewed the market opportunity and most important market segments. He also outlined the company's R&D pipeline and important milestones for 2012. The company recently completed an $8.5M public offering to fund its commercial and product development efforts. NeuroMetrix was founded in 1996 and has been publicly traded on Nasdaq since 2004, he noted.
NeuroMetrix was also recently featured in the Conservative Speculator which can be viewed at http://wallstreetcorner.com/cs/NURO.pdf About NeuroMetrix NeuroMetrix is a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes. The Company currently markets products for the detection, diagnosis, and monitoring of diabetic neuropathies such as diabetic peripheral neuropathy and median neuropathy (carpal tunnel syndrome). For more information, please visit http://www.neurometrix.com.
CONTACT: NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761 Chief Financial Officer email@example.com KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY MEDICAL DEVICES DIABETES SOURCE: NeuroMetrix, Inc.
Copyright Business Wire 2012 PUB: 03/26/2012 07:00 AM/DISC: 03/26/2012 07:00 AM http://www.businesswire.com/news/home/20120326005126/